EFG International AG Purchases New Shares in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• EFG International AG initiated a position in Regeneron Pharmaceuticals during the second quarter, purchasing 1,840 shares valued at approximately $1.15 million. Institutional investors collectively own 83.31% of REGN.
• Regeneron reported a strong latest quarter, with EPS of $14.29 versus the $10.16 consensus estimate and revenue of $4.29 billion, up 16.7% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $800.36.
• Despite constructive long-term sentiment, the company faces uncertainty from a securities lawsuit related to its Fianlimab-Libtayo melanoma study, while insiders sold 1,400 shares worth approximately $1.09 million over the past three months.

EFG International AG purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,840 shares of the biopharmaceutical company's stock, valued at approximately $1,147,000.

Other institutional investors have also recently added to or reduced their stakes in the company. SHP Wealth Management acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $26,000. Western Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at $26,000. Titan Wealth CI Ltd acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $29,000. Mowery & Schoenfeld Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at $29,000. Finally, Trust Co. of Vermont bought a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at $29,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Despite the setback, Wall Street remains generally constructive on Regeneron’s long-term growth prospects, and the shares have outperformed the broader S&P 500 over the past year. The company’s latest reported quarter also showed strong execution, with revenue up 16.7% year over year and EPS substantially above consensus estimates. Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?
• Neutral Sentiment: A reported August short-interest update showed zero shares sold short, but the figures appear incomplete or erroneous because the reported change was listed as “NaN.” It therefore provides little reliable information about current trading sentiment.
• Negative Sentiment: Several law firms announced or promoted a securities class action alleging that Regeneron misled investors about the viability and prospects of the Phase 3 Fianlimab-Libtayo melanoma study, including by emphasizing earlier-stage results and practice-changing expectations. The allegations have not been proven, but the litigation adds reputational, financial, and uncertainty-related overhang. Investors who purchased shares between August 1, 2025, and May 15, 2026, are being reminded of a September 14, 2026, deadline to seek lead-plaintiff status. Regeneron Investors: September 14, 2026 Lead Plaintiff Deadline

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reissued a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Wells Fargo & Company increased their price target on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an "equal weight" rating in a research report on Friday, July 31st. Morgan Stanley lifted their price target on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an "equal weight" rating in a research note on Friday, July 31st. Piper Sandler lowered their price objective on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating for the company in a report on Thursday, July 9th. Finally, Cantor Fitzgerald upped their price objective on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an "overweight" rating in a research note on Friday, July 31st. Fifteen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $800.36.

Insider Buying and Selling

In other news, Director Arthur F. Ryan sold 200 shares of the business's stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the transaction, the director owned 17,303 shares of the company's stock, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the company's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the transaction, the director owned 603 shares of the company's stock, valued at approximately $482,400. This trade represents a 39.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,400 shares of company stock worth $1,090,030 in the last three months. 6.97% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Down 2.3%

REGN stock opened at $814.79 on Thursday. The firm has a market cap of $83.89 billion, a price-to-earnings ratio of 20.14, a PEG ratio of 1.42 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $847.00. The firm has a fifty day moving average price of $709.88 and a two-hundred day moving average price of $717.69. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company's revenue for the quarter was up 16.7% on a year-over-year basis. During the same period last year, the firm posted $12.81 EPS. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio is 9.29%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source